Another phase I clinical trial (NCT03608618) evaluated MCY-M11, a mesothelin-directed CAR mRNA transfected into peripheral blood mononuclear cells, in patients with ovarian carcinoma and malignant peritoneal mesothelioma was terminated due to a sponsor shift in focus [71]. Here, MSLN is linked to ovarian carcinoma.